<?xml version='1.0' encoding='UTF-8'?>
<rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0">
  <channel>
    <title>Best Of Week - Head &amp; Neck Cancer</title>
    <link>https://pubmed.ncbi.nlm.nih.gov</link>
    <description>Top 10 most impactful head and neck cancer papers this week, selected by AI</description>
    <lastBuildDate>Fri, 13 Feb 2026 06:49:37 +0000</lastBuildDate>
    <item>
      <title>#1 [90/100] Final survival analysis of induction chemotherapy with lobaplatin and fluorouracil versus cisplatin and fluorouracil followed by concurrent chemoradiotherapy in nasopharyngeal carcinoma: a multicenter, randomized, phase 3 trial.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41667463/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41667463/</guid>
      <dc:creator>Cao X, Zhou JY, Huang HY, Guo L, Huang YY, Qiu WZ, Lin ZC, Cao KJ, Mo HY, Li XM, et al.</dc:creator>
      <pubDate>Tue, 10 Feb 2026 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;üî• CRITICAL - Score: 90/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This multicenter, randomized phase 3 trial presents long-term survival data comparing a novel induction chemotherapy regimen with a standard treatment in nasopharyngeal carcinoma, demonstrating non-inferior outcomes and fewer toxic effects, indicating potential practice-changing implications.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Cao X, Zhou JY, Huang HY, Guo L, Huang YY, Qiu WZ, Lin ZC, Cao KJ, Mo HY, Li XM, et al.&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; Nature communications | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1038/s41467-026-69315-1'&gt;10.1038/s41467-026-69315-1&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2026-Feb-10&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41667463/'&gt;41667463&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;In nasopharyngeal carcinoma, cisplatin is known to be associated with poor treatment compliance and notable side effects. More effective and safer platinum drugs are needed for the treatment of patients with nasopharyngeal carcinoma. In 2021, our multicenter, randomized, phase 3 trial reported that lobaplatin and fluorouracil induction chemotherapy plus concurrent chemoradiotherapy resulted in non-inferior survival and fewer toxic effects than did cisplatin-based therapy in nasopharyngeal carcinoma. Data from the 10-year survival analysis are updated here. With a median follow-up of 10.6 years in the intention-to-treat population, 10-year progression-free survival is 70.7% in the lobaplatin-based therapy group vs. 71.9% in the cisplatin-based therapy group (HR 1.02, 95% CI 0.72-1.43; log-rank p‚Äâ=‚Äâ0.885). The difference between the groups is 1.2% (95% CI -6.7-9.1, pnon-inferiority‚Äâ=‚Äâ0.015), which is lower than the prespecified non-inferiority margin of 10%. The results are similar when we analyze patients in the per-protocol population. In the univariable and multivariable analyses, stage is an independent prognostic factor for progression-free survival (p‚Äâ=‚Äâ0.001). The subgroup analyses suggest that the non-inferiority of lobaplatin-based therapy did not differ among specific populations. The incidence of late toxic effects is similar between the therapy groups, except¬†for grades 1-2 peripheral neuropathy (p‚Äâ=‚Äâ0.033), grades 1-2 deafness/otitis (p‚Äâ=‚Äâ0.021), and grades 1-2/3 nephrotoxicity (p‚Äâ=‚Äâ0.005; p‚Äâ=‚Äâ0.021), the incidence of which is greater in the cisplatin-based therapy group than in the lobaplatin-based therapy group. Our findings suggest that lobaplatin and fluorouracil induction chemotherapy plus lobaplatin-based concurrent chemoradiotherapy is an alternative doublet treatment strategy to cisplatin-based concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma.</description>
    </item>
    <item>
      <title>#2 [90/100] Standard chemoradiotherapy with concurrent and adjuvant camrelizumab in patients with high risk nasopharyngeal carcinoma: multicentre, randomised, open label, phase 3 trial.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41667193/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41667193/</guid>
      <dc:creator>You R, Xu GQ, Ding X, Liang JH, Liu ZG, Zou X, Liu YP, Hu GY, Liu YM, Duan CY, et al.</dc:creator>
      <pubDate>Tue, 10 Feb 2026 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;üî• CRITICAL - Score: 90/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This is a multicentre, randomized, open-label phase 3 trial assessing a novel therapy (camrelizumab) in combination with standard chemoradiotherapy for high-risk nasopharyngeal carcinoma, which has the potential to change treatment paradigms and improve patient outcomes.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; You R, Xu GQ, Ding X, Liang JH, Liu ZG, Zou X, Liu YP, Hu GY, Liu YM, Duan CY, et al.&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; BMJ (Clinical research ed.) | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1136/bmj-2025-085863'&gt;10.1136/bmj-2025-085863&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2026-Feb-10&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41667193/'&gt;41667193&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;OBJECTIVE: To assess treatment with camrelizumab (a programmed death 1 inhibitor) in addition to concurrent chemoradiotherapy and as a maintenance treatment in patients with high risk nasopharyngeal carcinoma. DESIGN: Multicentre, randomised, open label, phase 3 trial. SETTING: Seven hospitals in China between 18 August 2020 and 21 June 2022. PARTICIPANTS: Adults aged 18-70 years with newly diagnosed high risk nasopharyngeal carcinoma after three cycles of induction chemotherapy with gemcitabine and cisplatin (stage 4a, stage 2-3 with stable or progressive disease, or detectable Epstein-Barr virus DNA). INTERVENTIONS: Patients were randomly assigned (1:1) to receive combination chemoradiotherapy based on cisplatin (standard treatment group) or standard treatment with 19 cycles of intravenous camrelizumab (200 mg) once every three weeks (radiotherapy plus two concurrent cycles and 17 adjuvant cycles; camrelizumab group). MAIN OUTCOME MEASURES: The primary endpoint in the intention-to-treat group was progression-free survival, defined as the time from randomisation to disease recurrence (locoregional or distant) or death from any cause. Secondary endpoints included safety and overall survival. RESULTS: 390 patients were enrolled and randomly assigned to the camrelizumab group (n=194) or the standard treatment group (n=196). At median follow-up of 39.9 months (interquartile range 36.8-43.4 months), progression-free survival was higher in the camrelizumab group than the standard treatment group (36 months: 83.4%, 95% confidence interval 78.3% to 88.8% v 71.3%, 65.2% to 77.9%; stratified hazard ratio 0.51, 95% confidence interval 0.34 to 0.77, P=0.001). The incidence of acute and late adverse events (grade 3 or 4) was 50.5% and 3.2% in the camrelizumab group compared with 48.7% and 3.7% in the standard treatment group. Immunological adverse events (grade 3 or 4) occurred in 19 patients (10.2%) in the camrelizumab group. CONCLUSION: The addition of camrelizumab to concurrent chemoradiotherapy and as a maintenance treatment improved progression-free survival among patients with high risk nasopharyngeal carcinoma after induction chemotherapy. TRIAL REGISTRATION: ClinicalTrials.gov NCT04453826.</description>
    </item>
    <item>
      <title>#3 [75/100] Proposed Version Nine of the AJCC and UICC TNM Classification for Salivary Gland Carcinoma.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41678147/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41678147/</guid>
      <dc:creator>Huang SH, Cotler J, Palis B, Seethala RR, Hosni A, O'Sullivan B, Vander Poorten V, Bishop JA, Glastonbury CM, Beadle B, et al.</dc:creator>
      <pubDate>Thu, 12 Feb 2026 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;‚ú® NOTABLE - Score: 75/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This study proposes a novel TNM classification for salivary gland carcinoma, which could enhance prognostic accuracy and clinical decision-making, although it is based on retrospective data and does not constitute a randomized trial.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Huang SH, Cotler J, Palis B, Seethala RR, Hosni A, O'Sullivan B, Vander Poorten V, Bishop JA, Glastonbury CM, Beadle B, et al.&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; JAMA otolaryngology-- head &amp; neck surgery | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1001/jamaoto.2025.5396'&gt;10.1001/jamaoto.2025.5396&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2026-Feb-12&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41678147/'&gt;41678147&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;IMPORTANCE: A unified salivary gland carcinoma (SGC)-specific tumor-node-metastasis (TNM) classification can enhance prognostic accuracy, support clinical decision-making, and improve the quality of patient care. OBJECTIVE: To derive and validate an SGC-specific pTNM classification with improved prognostic accuracy and optimized stage distribution for version nine of the American Joint Committee on Cancer/Union for International Cancer Control staging protocol. DESIGN, SETTING, AND PARTICIPANTS: This retrospective prognostic cohort study derived a novel pTNM classification using data from the National Cancer Database (NCDB) of patients with surgically treated major SGC (2012-2017) and validated it in an international major SGC cohort (2008-2021) and a single-institution minor SGC cohort (Memorial Sloan Kettering Cancer Center; 1985-2016). Data were analyzed from June to November 2024. EXPOSURES: Surgery with or without postoperative radiotherapy or chemoradiotherapy. MAIN OUTCOMES AND MEASURES: The primary end point was overall survival (OS). Cox proportional hazards multivariable analysis was used to confirm the prognostic importance of pathologically positive lymph node (LN) number and extranodal extension (pENE) and derive an optimal pTNM classification. RESULTS: The NCDB dataset included 8409 patients with SGC: 7659 with M0 disease (5748 with pN0 disease and 1911 with pN+ disease) and 750 with M1 disease. Among the 7659 patients with M0 disease, the median (IQR) age was 60 (48-71) years, and 3861 (50.4%) were male. The median (IQR) follow-up was 88.4 (72.3-108.5) months. The 5-year OS was 87.2% (95% CI, 86.3-88.0) for N0 disease, 68.2% (95% CI, 63.9-72.8) for 1 positive LN without pENE, 60.2% (95% CI, 53.5-67.5) for 2 positive LNs without pENE, 68.4% (95% CI, 58.0-76.6) for 3 positive LNs without pENE, 47.5% (95% CI, 41.6-52.8) for more than 3 positive LNs without pENE, and 41.4% (38.1-44.8) for pENE-positive LNs. Multivariable analysis confirmed the independent prognostication of LN count compared with pN0 disease (1 positive LN: adjusted hazard ratio [aHR], 1.70; 95% CI, 1.44-2.01; 2 positive LNs: aHR, 1.61; 95% CI, 1.31-1.98; 3 positive LNs: aHR, 2.10; 95% CI, 1.65-2.68; 4 positive LNs : aHR, 2.46; 95% CI, 1.87-3.24; more than 4 positive LNs: aHR, 2.07; 95% CI, 2.08-2.91) and pENE-positive LNs compared with pENE-negative LNs (aHR, 1.27; 95% CI, 1.10-1.48). The proposed pN classification were pN1 for 1 to 3 positive LNs and pENE negativity and pN2 for more than 3 positive LNs or pENE positivity. Model fit improved with the proposed pN classification vs the current pN classification (Akaike Information Criterion, 26‚ÄØ442 vs 26‚ÄØ483). Based on the aHR model, the following stage groups were proposed: stage I: T1N0 (1 [reference]); stage II: T2N0 (aHR, 1.34; 95% CI, 1.11-1.61); stage IIIA: T1-2N1 or T3-4N0 (aHR, 2.36; 95% CI, 1.99-2.80); stage IIIB: T1-2N2 or T3-4N1-2 (aHR, 5.15; 95% CI, 4.38-6.06); and stage IV: M1 disease (aHR, 13.61; 95% CI, 11.37-16.29). The C index values were similar (proposed classification: 0.792; current classification: 0.790), while the AIC improved slightly (proposed classification: 26‚ÄØ441; current classification: 26‚ÄØ482). Stage-specific OS differences were evident in both the international major SGC cohort (n‚Äâ=‚Äâ1015) and Memorial Sloan Kettering Cancer Center minor SGC cohort (n‚Äâ=‚Äâ444). CONCLUSIONS AND RELEVANCE: This unified, SGC-specific staging system improved prognostic accuracy and sample size balance and was applicable to both major and minor SGCs.</description>
    </item>
    <item>
      <title>#4 [75/100] Bridging the Gap: What We Can Learn From LEAP-010 in Recurrent/Metastatic Head and Neck Cancer.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41671524/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41671524/</guid>
      <dc:creator>Xiang J, Geiger JL</dc:creator>
      <pubDate>Wed, 11 Feb 2026 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;‚ú® NOTABLE - Score: 75/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; The paper discusses insights from a significant study in recurrent/metastatic head and neck cancer published in a high-impact journal, suggesting potential clinical implications and novel findings that may influence treatment approaches.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Xiang J, Geiger JL&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; Journal of clinical oncology : official journal of the American Society of Clinical Oncology | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1200/JCO-25-02640'&gt;10.1200/JCO-25-02640&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2026-Feb-11&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41671524/'&gt;41671524&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;i&gt;No abstract available&lt;/i&gt;</description>
    </item>
    <item>
      <title>#5 [75/100] Androgen Receptor Signaling Induces CD8‚Å∫ T Cell Dysfunction that is Reversed by Androgen Deprivation Therapy in Male Head and Neck Squamous Cell Carcinoma.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41661680/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41661680/</guid>
      <dc:creator>Wang Q, Tan Z, Zheng C, Xu J, Li Q, Hong S, Yu D, Hu X, Wang J, Jiang L, et al.</dc:creator>
      <pubDate>Mon, 09 Feb 2026 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;‚ú® NOTABLE - Score: 75/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This study identifies a novel mechanism by which androgen receptor signaling affects CD8‚Å∫ T cell function in HNSCC and suggests a potential therapeutic strategy with androgen deprivation therapy, indicating moderate impact on clinical practice and understanding of disease biology.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Wang Q, Tan Z, Zheng C, Xu J, Li Q, Hong S, Yu D, Hu X, Wang J, Jiang L, et al.&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; Cancer research | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1158/0008-5472.CAN-25-2384'&gt;10.1158/0008-5472.CAN-25-2384&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2026-Feb-09&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41661680/'&gt;41661680&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;Head and neck squamous cell carcinoma (HNSCC) exhibits a distinct sex disparity in incidence, with a higher incidence in males than females. Recent studies have suggested that this difference persists even after accounting for smoking and alcohol use, highlighting the need to elucidate the underlying biological mechanisms. In this study, we demonstrated that sex differences in HNSCC are androgen-dependent and identified androgen receptor (AR) signaling as a key regulator of the tumor immune microenvironment by modulating CD8‚Å∫ T cell differentiation and function. Mechanically, early growth response 4 (EGR4) functioned as a direct downstream transcriptional effector of AR that induced CD8‚Å∫ T cell dysfunction. Clinically, androgen deprivation therapy (ADT) was an effective therapeutic strategy in HNSCC, suppressing tumor growth in mice while improving intratumoral CD8‚Å∫ T cell function. Moreover, combining ADT with immune checkpoint inhibitors led to improved antitumor efficacy. Together, these findings reveal ADT as a promising therapeutic approach to enhance the antitumor activity of sex-biased CD8‚Å∫ T cells in HNSCC, which could inform the development of sex-biased immunotherapies for treating HNSCC patients.</description>
    </item>
    <item>
      <title>#6 [75/100] Paclitaxel plus cetuximab for the treatment of R/M SCCHN after first-line pembrolizumab failure: primary analysis from the PaceAce trial.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41650746/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41650746/</guid>
      <dc:creator>Fuereder T, Klinghammer K, Hahn D, Gr√ºnberger B, Melchardt T, Greil R, Kocher F, Gamerith G, Wagner C, Berchtold L, et al.</dc:creator>
      <pubDate>Thu, 05 Feb 2026 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;‚ú® NOTABLE - Score: 75/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; The study addresses a critical evidence gap in the treatment of R/M SCCHN after pembrolizumab failure, presenting a novel combination therapy with potential clinical implications, although it is not a phase 3 trial and is published in a specialty journal.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Fuereder T, Klinghammer K, Hahn D, Gr√ºnberger B, Melchardt T, Greil R, Kocher F, Gamerith G, Wagner C, Berchtold L, et al.&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; ESMO open | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1016/j.esmoop.2026.106061'&gt;10.1016/j.esmoop.2026.106061&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2026-Feb-05&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41650746/'&gt;41650746&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;BACKGROUND: No standard second-line treatment has been established for patients with recurrent or metastatic (R/M) squamous-cell carcinoma of the head and neck (SCCHN) progressing after first-line pembrolizumab-based therapy, representing a critical evidence gap in current clinical practice. PATIENTS AND METHODS: Patients with R/M SCCHN of the oropharynx, hypopharynx, larynx, or oral cavity, progressing after first-line pembrolizumab-based regimens, received paclitaxel (PTX) 175 mg/m2 every 21 days plus weekly cetuximab (C) 250 mg/m2 for up to six cycles, followed by C maintenance. The primary endpoint was overall response rate (ORR) at 12 weeks. Secondary endpoints included best overall response (BoR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), duration of response (DoR), quality of life, and safety. RESULTS: Fifty-seven patients were enrolled (median age 64 years). Twenty-five patients (43.9%) had a primary tumor in the oropharynx, 17 (29.8%) in the oral cavity, 9 (15.8%) in the hypopharynx, and 6 (10.5%) in the larynx. The ORR was 43.9% [95% confidence interval (CI) 30.7% to 57.6%], the BoR was 47.4% (95% CI 34.0% to 61.0%) with nine (15.8%) complete responses, and the DCR was 71.9% (95% CI 58.5% to 83.0%). DoR was 5.7 months (95% CI 5.1 months-not reached). Median PFS and OS were 5.9 months (95% CI 5.5-8.4 months) and 12.2 months (95% CI 10.5-17.6 months), respectively. Six-month PFS and OS rates were 49.0% and 73.0%, respectively. The most frequent non-hematological treatment-related adverse events were C-associated skin rash (78.9%) and PTX-related polyneuropathy (35.1%). CONCLUSIONS: This is the first prospective trial specifically evaluating PTX plus C after failure of first-line pembrolizumab-based therapy in patients with R/M SCCHN. The observed clinical activity and tolerability support this widely available regimen as a potential standard-of-care option in the absence of randomized evidence in this setting.</description>
    </item>
    <item>
      <title>#7 [70/100] A tumor DNA-Methylome derived signature of Hypoxia Identifies HPV-negative head and neck cancer patients at risk for distant metastasis after postoperative radiochemotherapy (PORT-C).</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41672251/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41672251/</guid>
      <dc:creator>Tawk B, Halec G, Rein K, Schwager C, Knoll M, Wirkner U, Held T, Weykamp F, Liermann J, Hoerner-Rieber J, et al.</dc:creator>
      <pubDate>Mon, 09 Feb 2026 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;‚ú® NOTABLE - Score: 70/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This study validates a tumor DNA methylation signature in a multicenter cohort of HPV-negative HNSCC patients, providing important insights into risk stratification for distant metastasis after postoperative radiochemotherapy, though it is a phase of validation rather than a primary trial.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Tawk B, Halec G, Rein K, Schwager C, Knoll M, Wirkner U, Held T, Weykamp F, Liermann J, Hoerner-Rieber J, et al.&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1016/j.radonc.2026.111433'&gt;10.1016/j.radonc.2026.111433&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2026-Feb-09&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41672251/'&gt;41672251&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;BACKGROUND AND PURPOSE: Tumor hypoxia is a predictive biomarker of treatment resistance in patients with head and neck squamous cell carcinoma (HNSCC). We previously reported the discovery of a tumor DNA methylation signature of hypoxia (Hypoxia-M), identifying HNSCC patients at risk for local recurrence (LR), all event progression, and death after primary radiochemotherapy (RCHT). We further validate Hypoxia-M in an independent cohort of HNSCC patients who underwent surgical resection followed by postoperative radiochemotherapy (PORT-C) METHODS: Hypoxia-M was validated in HPV-negative HNSCC patients (n‚ÄØ=‚ÄØ134) homogeneously treated with PORT-C in the frame of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG) multicenter biomarker trial. DNA methylation was profiled using Illumina450K technology. The performance of Hypoxia-M was integrated with previously reported biomarkers, including gene expression signatures (GES) of hypoxia, a methylome-based HPV-Independent Classifier of disease Recurrence (HICR), and immune cell score using immunohistochemistry (CD3/CD8/PD-L1/PD1). RESULTS: Hypoxia-M was independently prognostic for overall survival (OS, HR‚ÄØ=‚ÄØ2.34, p‚ÄØ=‚ÄØ0.03) and distant metastasis (DM, HR‚ÄØ=‚ÄØ4.3, p‚ÄØ=‚ÄØ0.001), but not for LR after PORT-C. Hypoxia-M remained significant after adjusting for patient≈õ age, gender, smoking status, tumor stage, and high-risk features (ECE&amp;/R1 resection). Hypoxia-M status was inversely associated with CD8 T-cell infiltration. Patient stratification improved by integrating previously reported biomarkers, with Hypoxia-M demonstrating independent prognostic performance. CONCLUSIONS: The prognostic utility of Hypoxia-M was validated in an independent cohort. Our results highlighted a difference in recurrence patterns of hypoxic tumors treated in the primary setting (local recurrence) versus postoperatively (distant metastasis) and the utility of Hypoxia-M for identifying the main pattern of recurrence.</description>
    </item>
    <item>
      <title>#8 [70/100] The impact of tobacco cessation on buccal mucosa cancer risk: A multi-centre case-control study in India.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41657059/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41657059/</guid>
      <dc:creator>Pullat GB, Bohrmann B, George GS, Dikshit S, Singh A, Chaturvedi P, Dikshit R, Lewington S, Mhatre S</dc:creator>
      <pubDate>Mon, 09 Feb 2026 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;‚ú® NOTABLE - Score: 70/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This multi-centre case-control study with a large sample size provides important insights into the effects of tobacco cessation on buccal mucosa cancer risk, which could have implications for public health and prevention strategies, although it is not a randomized controlled trial.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Pullat GB, Bohrmann B, George GS, Dikshit S, Singh A, Chaturvedi P, Dikshit R, Lewington S, Mhatre S&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; International journal of cancer | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1002/ijc.70372'&gt;10.1002/ijc.70372&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2026-Feb-09&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41657059/'&gt;41657059&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;While the association between tobacco consumption and oral cancer is well established, the effect of tobacco cessation, particularly chewing tobacco, is less extensively studied. We aim to explore the effect of tobacco cessation on the risk of buccal mucosa cancer (BMC). A case-control study was conducted across five cancer centres in India. We enrolled 2320 BMC and 2302 frequency-matched controls. Information was collected on smoking and chewing (products, duration and quitting). Unconditional logistic regression models were used to estimate odds ratios (OR) and 95% confidence intervals (95% CI) of the effect of tobacco cessation compared to current users, after adjusting for potential confounders. For both smoking and chewing, the odds reduced rapidly after 5‚Äâyears of quitting, so that those who had quit smoking ‚â•10‚Äâyears ago had only 0.39 (95% CI 0.28-0.54) the odds of BMC compared to those who continued to smoke, and those who quit chewing ‚â•10‚Äâyears ago had 0.58 (95% CI 0.43-0.81) the odds of BMC compared to those who continued to chew. Chewing with areca nut was associated with almost double the risk of chewing without (OR 1.86, 95% CI 1.53-2.26) but the rate of reduction of risk with quitting was similar. These findings show clearly the benefits of quitting and inform policies that emphasize chewing tobacco cessation, given its widespread prevalence in India.</description>
    </item>
    <item>
      <title>#9 [70/100] Prognostic significance of extranodal extension in cervical lymph node metastases of head and neck squamous cell carcinoma: A systematic review and meta-analysis with bibliometric overview.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41655423/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41655423/</guid>
      <dc:creator>Singh SP, Prasad S, Dean PM, Kujur AL, Jaiswal G</dc:creator>
      <pubDate>Sat, 07 Feb 2026 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;‚ú® NOTABLE - Score: 70/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This systematic review and meta-analysis addresses an important prognostic factor in head and neck squamous cell carcinoma, providing valuable insights into survival impact and research trends, but lacks the definitive evidence or practice-changing findings characteristic of higher-impact studies.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Singh SP, Prasad S, Dean PM, Kujur AL, Jaiswal G&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; Oral oncology | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1016/j.oraloncology.2026.107862'&gt;10.1016/j.oraloncology.2026.107862&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2026-Feb-07&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41655423/'&gt;41655423&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;OBJECTIVE: Extranodal extension (ENE) of cervical lymph node metastases is a key prognostic factor in head and neck squamous cell carcinoma (HNSCC). This systematic review and meta-analysis evaluated the survival impact of ENE in HNSCC and identified global research trends relevant to this research field through a complementary bibliometric analysis. MATERIALS AND METHODS: ScienceDirect, PubMed, and Scopus were systematically searched during 2000-2025. A systematic review and a meta-analysis were conducted in accordance with the PRISMA 2020 guidelines. A Scopus-based bibliometric analysis was conducted using the Biblioshiny package of R to identify and map the publication trends, influential authors, and major institutional contributions between 2010 and 2025. RESULTS: Of the 839 retrieved records, 711 studies were screened, and 16 studies comprising approximately 3900 patients met all inclusion criteria. The bibliometric analysis of 120 Scopus-indexed publications demonstrated a marked increase in ENE-related research from 2015 onward, driven primarily by institutions in Australia, Taiwan, and South Korea. Keyword mapping indicated expanding intersections of ENE research with radiomics, prognostic modelling, and refinement of staging systems. Meta-analysis confirmed a significant association between ENE and adverse survival outcomes. Subgroup analyses showed consistently poor prognostic implications across both pathologic and radiologic ENE assessments. CONCLUSION: ENE in cervical lymph node metastases is an independent and strong predictor of adverse survival in HNSCC. The increasing global attention to ENE highlights its crucial role in multidisciplinary oncologic management. Therefore, standardized pathological and imaging-based assessment of ENE is essential for developing superior prognostic models and optimizing future treatment planning strategies.</description>
    </item>
    <item>
      <title>#10 [70/100] Intraoperative Margin Assessment Methods in Oral Cavity Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41649240/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41649240/</guid>
      <dc:creator>Caraway J, Millay D, Zarrella D, Kim HE, Wrozek T, Yang A, Zamani M, Watson N, Heckman C, Garrett S, et al.</dc:creator>
      <pubDate>Fri, 06 Feb 2026 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;‚ú® NOTABLE - Score: 70/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This systematic review and meta-analysis addresses an important clinical question regarding intraoperative margin assessment methods in oral cavity squamous cell carcinoma, providing valuable insights that could influence surgical practices, though it does not present new clinical trial data or practice-changing findings.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Caraway J, Millay D, Zarrella D, Kim HE, Wrozek T, Yang A, Zamani M, Watson N, Heckman C, Garrett S, et al.&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1002/ohn.70136'&gt;10.1002/ohn.70136&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2026-Feb-06&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41649240/'&gt;41649240&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;OBJECTIVE: Currently, there is a lack of consensus regarding the superiority of specimen-based versus tumor bed-based intraoperative margin analysis in oral cavity squamous cell carcinoma (OCSCC). The purpose of this study is to perform the first meta-analysis examining intraoperative margin assessment methods in OCSCC with the goal of determining if there is a significant difference in patient outcomes between specimen-driven and tumor bed-driven margin analysis. DATA SOURCES: A comprehensive search of the literature was performed using PubMed, Embase, and Web of Science. REVIEW METHODS: Studies met inclusion criteria if they conducted intraoperative specimen-driven and tumor bed-driven margin analysis in patients with OCSCC and reported patient outcomes. Random effects meta-analyses were used to analyze the compiled data. RESULTS: The literature search returned 1988 articles for initial review of which 9 (1240 participants) met criteria for inclusion and meta-analysis. Meta-analysis revealed that a specimen-based approach is associated with higher intraoperative re-resection rate (P‚Äâ&lt;‚Äâ.05), significantly lower final positive margin rate (P‚Äâ&lt;‚Äâ.05), and decreased local recurrence when compared to the tumor bed-based approach (P‚Äâ&lt;‚Äâ.05). However, there was no significant difference in overall recurrence when comparing intraoperative margin analysis methods (P‚Äâ&gt;‚Äâ.05). Additionally, none of the included studies noted a significant difference in survival outcomes between tumor bed versus specimen-based methods. CONCLUSION: Specimen-based frozen margin analysis in OCSCC results in lower false negative rates and improved local control; however, there is no significant difference in overall recurrence or survival when comparing specimen-based vs tumor bed-based techniques.</description>
    </item>
  </channel>
</rss>
